Myeloproliferative Disorders Archives - Insights

Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

Barbara J. Toman — Tue, 30 Apr 2024 13:00:00 +0000

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

The post Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D. appeared first on Insights.

Mayo Clinic-developed mass spectrometry assay improves detection of monoclonal proteins, advancing outcomes in hard-to-treat diseases

Mayo Clinic Laboratories — Tue, 16 Mar 2021 14:00:00 +0000

The assay is now recommended for diagnosing and monitoring patients with monoclonal protein disorders and exclusively available through Mayo Clinic Laboratories– Rochester.

The post Mayo Clinic-developed mass spectrometry assay improves detection of monoclonal proteins, advancing outcomes in hard-to-treat diseases appeared first on Insights.

BCR/ABL1 Testing [Test in Focus]

Alyssa Frank — Tue, 16 Jul 2019 16:35:44 +0000

David Viswanatha, M.D., a hematopathologist and co-director of the molecular hematology and complete genome sequencing laboratories at Mayo Clinic, provides an overview of BCR/ABL1 testing, discusses the best testing methods, NCCN/ELN criteria guidelines, why FISH testing is no longer routinely available at Mayo Clinic, and what test to order at what time for CML patients.

The post BCR/ABL1 Testing [Test in Focus] appeared first on Insights.

Myeloproliferative Neoplasm: Morphology, Molecular Updates and Cost-Effective Test Utilization

MCL Education — Wed, 15 Jul 2015 19:09:18 +0000

The diagnosis of Myeloproliferative Neoplasm (MPN) must include an integrated approach and combine the clinical findings with laboratory results. In our latest “Hot Topic,” Rong He, M.D., discusses the subclassification of MPNs and the use of JAK2, CALR, and MPL mutational analysis in diagnosis and prognosis.

The post Myeloproliferative Neoplasm: Morphology, Molecular Updates and Cost-Effective Test Utilization appeared first on Insights.

Myeloid Blast and Maturation Assessment by Flow Cytometry (“MDS Flow”)

MCL Education — Wed, 01 Jul 2015 15:01:58 +0000

Flow cytometric immunophenotyping method can be useful in assessing myeloid dysmaturation. In this “Hot Topic,” Dragon Jevremovic, M.D., Ph.D., describes a new flow cytometric test to detect aberrant patterns of expression in the diagnosis of myelodysplastic syndrome.

The post Myeloid Blast and Maturation Assessment by Flow Cytometry (“MDS Flow”) appeared first on Insights.